Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne: Cochrane systematic review

Abstract

Assessed as up to date: 2008/04/07

Background

Hirsutism is the presence of excessive hair growth in women and is an important cosmetic condition often resulting in severe distress. The most common cause is by increased production of male sex hormones (androgens). It is also affected by increased sensitivity to androgens in the hair follicles, and secretory glands around hair follicles (sebaceous glands). Spironolactone is an antiandrogen and aldosterone antagonist used to treat hirsutism.

Objectives

The objective was to investigate the effectiveness of spironolactone and/or in combination with steroids (oral contraceptive pill included) in reducing excess hair growth and/or acne in women.

Search strategy

The Cochrane Menstrual Disorders and Subfertility Group (MDSG) trials register was searched (April 2008). The Cochrane MDSG register is based on regular searches of MEDLINE, EMBASE, CINAHL, PsycINFO and CENTRAL, handsearching of 20 relevant journals and conference proceedings, and searches of several key grey literature sources. In addition, all reference lists of relevant trials were searched and drug companies contacted for details of unpublished trials.

Selection criteria

All randomised controlled comparisons of spironolactone versus: placebo, steroids (oral contraceptive pill included), spironolactone of varying dosages, or spironolactone and steroids versus steroids alone when used to reduce hair growth and acne in women.

Data collection and analysis

Nine trials were included in the review, eight trials were excluded. Two other trials are awaiting assessment. Only one trial studied acne as an outcome, the remainder were concerned with hirsutism. Major outcome measures include the following: subjective observations, Ferriman and Gallwey hair scores, hormonal and biochemical parameters, side effects, sebum production measurement.

Main results

In the two trials that compared 100 mg of spironolactone with placebo significant differences were reported for subjective improvements in hair growth (OR 7.18, 95% CI 1.96 to 26.28), although not the Ferriman-Galwey score (MD 7.20, 95% CI -10.98 to -3.42)). Data could not be otherwise pooled as only one trial reported an outcome.

Authors' conclusions

From the studies included in this review, there is some evidence to show that spironolactone is an effective treatment to decrease the degree of hirsutism but there was no evidence for effectiveness for the treatment of acne vulgaris. Studies in this area are scarce and small. Individual study data indicates some superiority of spironolactone over other drugs but results cannot be generalised.

Author(s)

Brown Julie, Farquhar Cindy, Lee Olivia, Toomath Robyn, Jepson Ruth G

Summary

Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne

The evidence suggests a lack of evidence to show whether spironolactone can reduce hirsutism and acne. Hirsutism in women (excessive hair growth) is most often caused by an increased production of male hormones. Spironolactone (쎦Aldactone' or 쎦Spirotone') is an anti-androgen, which can be taken with or without the oral contraceptive pill to try and reduce hirsutism. From the studies included in this review, there is some evidence to show that spironolactone is an effective treatment to decrease the degree of hirsutism, but insufficient evidence for the management of acne vulgaris. It appears to be more effective than finasteride 5mg/day, metformin and low dose cyproterone acetate.

Reviewer's Conclusions

Implications for practice

From the studies included in this review, there is some evidence to show that spironolactone is an effective treatment to decrease the degree of hirsutism, but insufficient evidence for the management of acne vulgaris. It is also clear that there are not appropriate tools to evaluate the effectiveness of these treatments adequately. Poor standard of research makes it difficult to determine the effectiveness of spironolactone in treatment of hirsutism and/or acne.

Implications for research

The limited number of randomised controlled studies on spironolactone highlights the need for more well designed studies involving a large sample size to investigate the properties of the drug. Outcome measures of acne and hirsutism need to be validated as accurate indications of severity of the conditions. The use of other drugs such as cyproterone acetate, said to be of comparative effectiveness to spironolactone, is investigated by another Cochrane review.

Get full text at The Cochrane Library

Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne: Cochrane systematic review is a sample topic from the Cochrane Abstracts.

To view other topics, please or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Learn more.

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne: Cochrane systematic review ID - 432264 BT - Cochrane Abstracts UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/432264/all/Spironolactone_versus_placebo_or_in_combination_with_steroids_for_hirsutism_and_or_acne:_Cochrane_systematic_review DB - Evidence Central DP - Unbound Medicine ER -